Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.
You may also be interested in...
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.
Schumer/Waxman Call For Industry Groups To Condemn Generic Drug Payoffs
In letters to PhRMA and GPhA, legislators point to FTC report detailing industry settlements as a sign of growing anti-competitive activity.
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.